We are a group of physicians that have developed a framework and rating system to evaluate therapies based on their patient-important benefits and harms as well as a system to evaluate diagnostics by patient sign, symptom, lab test or study.
We only use the highest quality, evidence-based studies (frequently, but not always Cochrane Reviews), and we accept no outside funding or advertisements.
Stents for Stable Coronary Artery Disease: NNH = 50 for serious complication (1/2018)
Statins in Persons at Low Risk of Cardiovascular Disease: No statistically significant mortality benefit (11/2017)
Neuraminidase Inhibitors Given for Influenza: Unclear benefits vs. harms (1/2010)
If you have suggestions, requests, or questions about a particular NNT review, please send us a message and we’ll try to address it as soon as possible.